Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Erythropoietin + Probiotic, EPO.
- Who it may be relevant to
- Registry conditions: Anaemia, Chronic Kidney Disease, Regular Hemodialysis. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Probiotic Supplementation on Resistant Anaemia to Erythropoietin in Chronic Kidney Disease Patients.
Overview
The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are: Can probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients. Participants will: Take Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms
Interventions
- Drug Erythropoietin + Probiotic
Anaemic chronic kidney disease patients on regular hemodialysis treated with Erythropoietin + Probiotic - Drug EPO
Anaemic chronic kidney disease patients on regular hemodialysis treated with Erythropoietin
Primary outcome measures
- - Hemoglobin concentration [Time frame: at baseline, and 3-months postintervention]
- - Erythropoietin resistance index (ERI) [Time frame: at baseline, and 3-months postintervention]
Secondary outcome measures (2)
- C-reactive protein [Time frame: at baseline, and 3-months postintervention]
- serum urea [Time frame: at baseline, and 3-months postintervention]
Eligibility criteria
Inclusion criteria
- Adult patients with end stage renal disease for more than 3 months on regular hemodialysis (GFR less than 15 ml/min/m2
- Receiving stable doses of erythropoietin therapy
- Able and willing to provide informed consent
Exclusion criteria
- Recent probiotic, antibiotic, or immunosuppressive therapy
- Microcytic hypochromic anemia.
- Patients with hyperparathyroidism
- Recent or planned kidney transplantation Gastrointestinal disorders (active IBD, cancer)
- Pregnancy or lactation
- Severe comorbidities (e.g., active infection, malignancies)
- Cognitive or physical inability to comply with protocol
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07296146 · 121-2025